NCT05725915

Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC

Multiparameter Prediction Model of Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer: a Real-world Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 56 (estimated)
• Sponsor: Beijing Red Clove Public Welfare Development Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.

Conditions

• Lung Cancer, Nonsmall Cell

Timeline

• Start date: 2022-12-01
• Primary completion: 2024-09-01
• Completion: 2025-03-01
• First posted: 2023-02-13
• Last updated: 2023-02-13

Locations

1 site across 1 country: China